Here, an integrated strategy was established by combining serum pharmacochemistry and network pharmacology to comprehensively and systematically investigate the components and mechanisms of XPF in treating CHD with depression, and validated in experiments. This evidence concerns the gene ERCC4 and depressive disorder.